bioAffinity Technologies, Inc. Logo

bioAffinity Technologies, Inc.

BIAF

(1.0)
Stock Price

0,97 USD

-196.42% ROA

-202.71% ROE

-2.28x PER

Market Cap.

23.607.978,00 USD

14.73% DER

0% Yield

-90.16% NPM

bioAffinity Technologies, Inc. Stock Analysis

bioAffinity Technologies, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

bioAffinity Technologies, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.46x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

4 ROE

Negative ROE (-95.33%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-111.22%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

bioAffinity Technologies, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

bioAffinity Technologies, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

bioAffinity Technologies, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

bioAffinity Technologies, Inc. Revenue
Year Revenue Growth
2019 0
2020 0 0%
2021 0 0%
2022 4.803 100%
2023 1.193.936 99.6%
2023 2.532.499 52.86%
2024 9.590.608 73.59%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

bioAffinity Technologies, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2019 1.852.589
2020 1.610.042 -15.06%
2021 1.326.050 -21.42%
2022 1.288.323 -2.93%
2023 1.321.504 2.51%
2023 1.724.597 23.37%
2024 1.815.580 5.01%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

bioAffinity Technologies, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 0
2020 994.343 100%
2021 880.772 -12.89%
2022 2.727.071 67.7%
2023 0 0%
2023 6.790.654 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

bioAffinity Technologies, Inc. EBITDA
Year EBITDA Growth
2019 -3.051.960
2020 -6.861.574 55.52%
2021 -1.476.653 -364.67%
2022 -5.821.090 74.63%
2023 -8.977.576 35.16%
2023 -7.723.640 -16.24%
2024 -7.746.920 0.3%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

bioAffinity Technologies, Inc. Gross Profit
Year Gross Profit Growth
2019 -40.278
2020 -22.242 -81.09%
2021 -4.817 -361.74%
2022 4.336 211.09%
2023 895.120 99.52%
2023 542.023 -65.14%
2024 3.355.488 83.85%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

bioAffinity Technologies, Inc. Net Profit
Year Net Profit Growth
2019 -3.307.499
2020 -7.268.737 54.5%
2021 -6.326.413 -14.9%
2022 -8.154.113 22.41%
2023 -9.163.536 11.02%
2023 -7.937.011 -15.45%
2024 -8.441.116 5.97%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

bioAffinity Technologies, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 0
2020 -1 0%
2021 -1 0%
2022 -2 100%
2023 -1 0%
2023 -1 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

bioAffinity Technologies, Inc. Free Cashflow
Year Free Cashflow Growth
2019 -2.501.595
2020 -2.210.527 -13.17%
2021 -2.048.978 -7.88%
2022 -4.290.832 52.25%
2023 -1.532.682 -179.96%
2023 -6.060.708 74.71%
2024 -1.560.710 -288.33%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

bioAffinity Technologies, Inc. Operating Cashflow
Year Operating Cashflow Growth
2019 -2.490.196
2020 -2.207.639 -12.8%
2021 -2.048.978 -7.74%
2022 -4.070.845 49.67%
2023 -1.532.513 -165.63%
2023 -6.037.806 74.62%
2024 -1.532.425 -294%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

bioAffinity Technologies, Inc. Capital Expenditure
Year Capital Expenditure Growth
2019 11.399
2020 2.888 -294.7%
2021 0 0%
2022 219.987 100%
2023 169 -130069.82%
2023 22.902 99.26%
2024 28.285 19.03%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

bioAffinity Technologies, Inc. Equity
Year Equity Growth
2019 -4.035.540
2020 -15.072.863 73.23%
2021 -15.790.719 4.55%
2022 11.043.443 242.99%
2023 6.993.909 -57.9%
2023 4.855.255 -44.05%
2024 3.433.114 -41.42%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

bioAffinity Technologies, Inc. Assets
Year Assets Growth
2019 658.810
2020 145.605 -352.46%
2021 1.453.308 89.98%
2022 12.182.125 88.07%
2023 10.189.464 -19.56%
2023 8.221.552 -23.94%
2024 6.656.448 -23.51%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

bioAffinity Technologies, Inc. Liabilities
Year Liabilities Growth
2019 4.694.350
2020 15.218.468 69.15%
2021 17.244.027 11.75%
2022 1.138.682 -1414.38%
2023 3.195.555 64.37%
2023 3.366.297 5.07%
2024 3.223.334 -4.44%

bioAffinity Technologies, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.64
Net Income per Share
-0.77
Price to Earning Ratio
-2.28x
Price To Sales Ratio
3.23x
POCF Ratio
-2.84
PFCF Ratio
-3.33
Price to Book Ratio
5.81
EV to Sales
3.31
EV Over EBITDA
-2.96
EV to Operating CashFlow
-3.44
EV to FreeCashFlow
-3.41
Earnings Yield
-0.44
FreeCashFlow Yield
-0.3
Market Cap
0,02 Bil.
Enterprise Value
0,02 Bil.
Graham Number
2.28
Graham NetNet
-0.11

Income Statement Metrics

Net Income per Share
-0.77
Income Quality
0.8
ROE
-1.7
Return On Assets
-1.29
Return On Capital Employed
-2.06
Net Income per EBT
1
EBT Per Ebit
1.01
Ebit per Revenue
-0.89
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.58
Research & Developement to Revenue
0.24
Stock Based Compensation to Revenue
0.14
Gross Profit Margin
0.32
Operating Profit Margin
-0.89
Pretax Profit Margin
-0.9
Net Profit Margin
-0.9

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.62
Free CashFlow per Share
-0.62
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.01
Capex to Depreciation
0.11
Return on Invested Capital
-2.2
Return on Tangible Assets
-1.96
Days Sales Outstanding
79.61
Days Payables Outstanding
59.87
Days of Inventory on Hand
2.1
Receivables Turnover
4.58
Payables Turnover
6.1
Inventory Turnover
173.68
Capex per Share
0

Balance Sheet

Cash per Share
0,07
Book Value per Share
0,30
Tangible Book Value per Share
0.11
Shareholders Equity per Share
0.3
Interest Debt per Share
0.05
Debt to Equity
0.15
Debt to Assets
0.08
Net Debt to EBITDA
-0.07
Current Ratio
1.15
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
4310485
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.33
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
19627.5
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

bioAffinity Technologies, Inc. Dividends
Year Dividends Growth

bioAffinity Technologies, Inc. Profile

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

CEO
Ms. Maria Zannes J.D.
Employee
75
Address
22211 West Interstate 10
San Antonio, 78257

bioAffinity Technologies, Inc. Executives & BODs

bioAffinity Technologies, Inc. Executives & BODs
# Name Age
1 Mr. Xavier T. Reveles M.S.
Chief Operating Officer
70
2 Mr. Steven Girgenti
Founder & Executive Chairman of the Board
70
3 Mr. J. Michael Edwards CPA, M.B.A.
Chief Financial Officer & Principal Accounting Officer
70
4 Ms. Julie Anne Overton
Director of Communications
70
5 Mr. Timothy P. Zannes J.D.
Executive Vice President, Secretary & General Counsel
70
6 Ms. Maria Zannes J.D.
Founder, President, Chief Executive Officer & Director
70
7 Dr. William Bauta Ph.D.
Chief Science Officer
70
8 Mr. Dallas J. Coleman
Vice President of sales
70

bioAffinity Technologies, Inc. Competitors